HomeAI · summaries
Storia in 15 fonti
Экспериментальный препарат почти вдвое увеличил выживаемость пациентов с раком поджелудочной железы
Экспериментальный препарат daraxonrasib компании Revolution Medicines почти вдвое увеличил выживаемость пациентов с метастатическим раком поджелудочной железы…
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
pbs.org
Pancreatic cancer is deadly and difficult to treat. A new pill could change that
The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.
- ·
healio.com
Daraxonrasib offers ‘transformational’ benefit in metastatic pancreatic cancer
CHICAGO — The eagerly awaited full dataset from arguably the most pivotal pancreatic cancer trial in decades is now public.Based on the buzz it created among ASCO Annual Meeting…
- ·
nbcnews.com
After new drug’s ‘unprecedented’ results for pancreatic cancer, doctors look at other uses
The experimental drug daraxonrasib, which doubled survival time in patients with advanced pancreatic cancer, may also prove effective for lung, colon and ovarian cancers.
- ·
independent.co.uk
Daily pill almost doubles survival time for pancreatic cancer patients in new trial
Daraxonrasib has been hailed as ‘landscape-changing’ for people with the disease
- ·
Pancreatic cancer breakthrough as pill almost doubles survival time for patients
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or…
- ·
cbsnews.com
New drug nearly doubles survival rates in some pancreatic cancer patients, study says
New research shows a medication called daraxonrasib is helping people with advanced pancreatic cancer live longer.
- ·
fortune.com
Experimental pill nearly doubles survival time for people with advanced pancreatic cancer. 'I actually started crying' | Fortune
The drug is called daraxonrasib and it blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases — a target that had eluded treatment for…
- ·
calabria7.news
Tumore al pancreas, svolta dalla ricerca: il farmaco daraxonrasib raddoppia la sopravvivenza (Calabria 7)
Un nuovo studio clinico sta attirando grande attenzione nella comunità scientifica internazionale per i risultati ottenuti nel trattamento del tumore al
- ·
fanpage.it
Tumore al pancreas, pillola daraxonrasib raddoppia la sopravvivenza: “È una svolta, ho pianto quando ho visto i risultati”
Il farmaco daraxonrasib contro il cancro al pancreas ha dimostrato risultati rivoluzionari in un nuovo studio
- ·
newsbytesapp.com
This drug can double survival time for pancreatic cancer patients
A groundbreaking daily pill has been shown to double survival time for patients battling the world's deadliest cancer, marking a major advancement in medical research.
- ·
g4media.ro
STUDIU: Un nou medicament dublează perioada de supraviețuire pentru pacienții diagnosticați cu cancer pancreatic
S-a descoperit că o pastilă poate aproape dubla perioada de supraviețuire pentru pacienții cu cancer pancreatic avansat, experții descriind studiul clinic ca fiind revoluționar.
- ·
virgilio.it
Tumore al pancreas, la nuova cura con compresse di daraxonrasib dà speranza: come funziona la molecola
La molecola daraxonrasib raddoppia la sopravvivenza contro il tumore al pancreas: i dati promettenti dello studio clinico presentati all'Asco
- ·
eu.usatoday.com
Pancreatic cancer 'miracle' drug daraxonrasib doubles survival rate in new trial
The drug daraxonrasib nearly doubled the overall survival rates of pancreatic cancer patients. Here's how it works and who can get it.
- ·
theins.ru
Экспериментальный препарат почти вдвое увеличил выживаемость пациентов с раком поджелудочной железы
Экспериментальный препарат daraxonrasib компании Revolution Medicines почти вдвое увеличил выживаемость пациентов с метастатическим раком поджелудочной железы…
- ·
hindustantimes.com
Revolution Medicines' new cancer pill extends life: ‘Molecular glue’ works, study shows
While the drug is not a cure, researchers say it could meaningfully improve both the length and quality of life for patients with advanced disease. | World News
- ·
pharmaceutical-technology.com
ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer - Pharmaceutical Technology
The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.